Formulation of Cream Containing Bacteriophage for the Control of Pseudomonas aeruginosa
Article Sidebar
Main Article Content
Abstract
Burn injuries are the major public health concern. In case of infecting with drug resistant bacteria in the wound area, the wound healing becomes more difficult. Pseudomonas aeruginosa is an opportunistic bacterium frequently found in burns and is a major cause of death. Silver zinc sulfadiazine cream is the current treatment for burn wounds to inhibit microorganisms on the wound. However, it has side effects in some burn patients. The use of bacteriophages to treat bacterial infections is an alternative way to control drug resistant bacteria but bacteriophages have limitations in treating infectious skin lesions due to their instability to the environment. The development of methods to protect bacteriophage particles can increase the chances of bacteriophage survival. The objectives of this study were to isolate and characterize a lytic phage specific to P. aeruginosa and to use it as an ingredient in the basic formula of cetomacrogol cream to control the growth of P. aeruginosa. One isolate of bacteriophage designated bacteriophage SH2 was isolated from wastewater collected from a hospital wastewater treatment pond. The host range of bacteriophage SH2 was determined by the spot test against 18 bacterial strains. The result revealed that it had specific lytic activity against P. aeruginosa. The study of thermal and pH tolerance test of the bacteriophage SH2 demonstrated that it was stable at temperatures ranging from 40°C to 60°C and at pH ranging from 6 to 8. When bacteriophage SH2 was used as an ingredient in the basic formula of cetomacrogol cream and its concentration in the cream was adjusted to be 1.0x107 PFU/gram, it was found that the bacteriophage was able to inhibit P. aeruginosa on an agar plate. The survival rate of bacteriophage SH2 in the cream was 79.6% at 4°C in light protected container for 35 days. This study demonstrates the potential of bacteriophages to be used in cosmeceutical products.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของ วารสารวิทยาศาสตร์และเทคโนโลยี มหาวิทยาลัยอุบลราชธานี
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับมหาวิทยาลัยอุบลราชธานี และคณาจารย์ท่านอื่นๆในมหาวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
References
Akers, K.S. and et al. 2019. Diagnosis of burn sepsis using the FcMBL ELISA: A pilot study in critically ill burn patients. Open Forum Infectious Diseases. 6(Suppl. 2): S300.
Krishnan, P. and et al. 2013. Cause of death and correlation with autopsy findings in burns patients. Burns. 39(4): 583-588.
Maitz, J. and et al. 2023. Burn wound infections microbiome and novel approaches using therapeutic microorganisms in burn wound infection control. Advanced Drug Delivery Reviews. 196: 114769.
Ronat, J.B. and et al. 2014. Highly drug-resistant pathogens implicated in burn-associated bacteremia in an Iraqi burn care unit. PLoS One. 9(8): e101017.
Church, D. and et al. 2006. Burn wound infections. Clinical Microbiology Reviews. 19(2): 403-434.
Moss, L.S. 2004. Outpatient management of the burn patient. Critical Care Nursing Clinics of North America. 16(1): 109-117.
Gorka, R., Shalli, B. and Neeru, B. 2020. Transient leukopenia in post-burn patients treated with topical silver sulfadiazine cream: A retrospective study. International Journal of Medical and Health Research. 6(12): 118-119.
Penziner, S., Schooley, R.T. and Pride, D.T. 2021. Animal models of phage therapy. Frontiers in Microbiology. 12: 631794.
Sarker, S.A. and et al. 2016. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from Bangladesh. EbioMedicine. 4: 124-137.
Save, J. and et al. 2022. Bacteriophages combined with subtherapeutic doses of flucloxacillin act synergistically against Staphylococcus aureus experimental infective endocarditis. Journal of the American Heart Association. 11(3): e023080.
Abo-Elmaaty, S.A., El Dougdoug, N.K. and Hazaa, M.M. 2016. Improved antibacterial efficacy of bacteriophage-cosmetic formulation for treatment of Staphylococcus aureus in vitro. Annals of Agricultural Sciences. 61(2): 201-206.
Adams, M.H. Bacteriophages. New York: Interscience Publishers Inc.
Lu, Z. and et al. 2003. Isolation and characterization of a Lactobacillus plantarum bacteriophage, phiJL-1, from a cucumber fermentation. International Journal of Food Microbiology. 84(2): 225-235.
Sharma, S. and et al. 2021. Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa. Scientific Reports. 11: 19393.
Khalid, F. and et al. 2017. Efficacy of bacteriophage against multidrug resistant Pseudomonas aeruginosa isolates. The Southeast Asian Journal of Tropical Medicine and Public Health. 48(5): 1056-1062.
Shigehisa, R. and et al. 2016. Characterization of Pseudomonas aeruginosa phage KPP21 belonging to family Podoviridae genus N4-like viruses isolated in Japan. Microbiology and Immunology. 60(1): 64–67.
van Charante, F. and et al. 2019. Isolation of bacteriophages. In: Harper, D. and et al. (eds.) Bacteriophages. Edinburgh: Springer, Cham.
Slekovec, C. and et al. 2012. Tracking down antibiotic-resistant Pseudomonas aeruginosa isolates in a wastewater network. PLoS One. 7(12): e49300.
Kim, S. and et al. 2018. Characterization of a Salmonella Enteritidis bacteriophage showing broad lytic activity against Gram-negative enteric bacteria. Journal of Microbiology. 56(12): 917-925.
Buttimer, C. and et al. 2017. Things are getting hairy: Enterobacteria bacteriophage vB_PcaM_CBB. Frontiers in Microbiology. 8: 44.
Khawaja, K.A. and et al. 2016. A virulent phage JHP against Pseudomonas aeruginosa showed infectivity against multiple genera. Journal of Basic Microbiology. 56(10): 1090-1097.
Dabrowska, K. 2019. Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Medicinal Research Reviews. 39(5): 2000-2025.
Kong, S.J. and Park, J.H. 2020. Acid tolerance and morphological characteristics of five Weissella cibaria bacteriophages isolated from kimchi. Food Science and Biotechnology. 29(6): 873-878.
Akremi, I. and et al. 2022. Isolation and characterization of lytic Pseudomonas aeruginosa bacteriophages isolated from sewage samples from Tunisia. Viruses. 14(11): 2339.
Brown, T.L. and et al. 2016. The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes growth. PLoS One. 11(3): e0151184.
Brown, T.L. and et al. 2017. Bacteriophage formulated into a range of semisolid and solid dosage forms maintain lytic capacity against isolated cutaneous and opportunistic oral bacteria. Journal of Pharmacy and Pharmacology. 69(3): 244-253.
Brown, T.L. and et al. 2020. The varying effects of a range of preservatives on Myoviridae and Siphoviridae bacteriophages formulated in a semi-solid cream preparation. Letters in Applied Microbiology. 71(2): 203-209.
Merabishvili, M. and et al. 2017. Stability of bacteriophages in burn wound care products. PLoS One. 12(7): e0182121.
